(Q37925846)

25 August 2017

1 reference

title

Entinostat for treatment of solid tumors and hematologic malignancies (English)

1 reference

25 August 2017

1 reference

Jeffrey Knipstein

1

1 reference

PubMed ID

21888556

25 August 2017

Lia Gore

series ordinal

2

1 reference

PubMed ID

21888556

25 August 2017

language of work or name

English

0 references

publication date

2 September 2011

1 reference

Expert Opinion on Investigational Drugs

25 August 2017

1 reference

25 August 2017

20

1 reference

25 August 2017

1455-1467

1 reference

25 August 2017

10

1 reference

Identification of novel isoform-selective inhibitors within class I histone deacetylases

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Romidepsin for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylase inhibitors in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Potentiation of reactive oxygen species is a marker for synergistic cytotoxicity of MS-275 and 5-azacytidine in leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

DNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Sp1-mediated TRAIL induction in chemosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Deacetylation of the DNA-binding domain regulates p53-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Impact of histone deacetylase inhibitors SAHA and MS-275 on DNA repair pathways in human mesenchymal stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.613822

10.1517/13543784.2011.613822

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21888556